glp-1 ckd Real-World Evidence for Receptor Agonists Across the Spectrum – AJKD Blog image3.png

A Guide to Weight-Loss Medications goes beyond the headlines and onslaught of ads to truthfully explain in plain, understandable language how weight-loss medications, including GLP-1 drugs, such as Ozempic, Wegovy, Mounjaro, and Zepbound, could work for you to finally lose weight and keep it off

However, you may also experience serious side effects, and you will likely have to keep taking the drug forever because youre not addressing any of the underlying causes behind your weight gain or weight loss resistance

Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs

Retatrutide is a next level drug because it is a triple agonist, adding metabolic benefits to those provided by other drugs